Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study

被引：0
|
作者：
Zhou, F. [1 ]
Yang, L. [1 ]
Peng, J. [1 ]
Xu, H. [1 ]
Wu, H. [1 ]
Wang, Y. [1 ]
Long, X. [1 ]
Gao, Q. [2 ]
Shi, X. [3 ]
Gong, J. [4 ]
Hu, J. [3 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat Oncol Med Oncol, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[2] Huangmei Cty Peoples Hosp, Dept Radiat Oncol, Huanggang, Peoples R China
[3] Macheng Peoples Hosp, Dept Med Oncol, Macheng, Peoples R China
[4] Huangshi Cent Hosp, Dept Med Oncol, Huangshi, Hubei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
974P
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [41] Second- or Third-line Therapy for advanced Renal Cell Carcinoma after Anti-PD1/L Failure
    Rexer, Heidrun
    Banek, Severine
    Doehn, Christian
    AKTUELLE UROLOGIE, 2022, 53 (02) : 122 - 123
  • [42] Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study
    Xu, Jing
    Wang, Xin
    Jia, Zhenya
    Sun, Guoping
    MEDICINE, 2025, 104 (11)
  • [43] Second-Line or Third-Line Therapy for advanced Renal Cell Cancer after Anti-PD1/L Failure An open-label, randomized Phase-III Trial study of MK-6482 in Combination with Lenvatinib (MK-7902) versus Cabozantinib as Second-Line or Third-Line Therapy in Patients with advanced Renal Cell Cancer who had Disease Progression after prior Anti-PD-1/L1 Therapy (AN 53/20 of AUO, HIF-011)
    Rexer, H.
    Banek, S.
    Doehn, C.
    UROLOGE, 2022, 61 (02): : 239 - 240
  • [44] The efficacy and safety of anti-PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.
    Chen, Jiaying
    Ji, Qinghai
    Wang, Yu
    Huang, Naisi
    Hu, Jiaqian
    Wei, Wenjun
    Huang, Caiping
    Shen, Qiang
    Li, Duanshu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
    Xu, Xiaoling
    Huang, Zhiyu
    Zheng, Lei
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (11) : 2344 - 2354
  • [46] Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
    Garassino, Marina Chiara
    Cho, Byoung-Chul
    Kim, Joo-Hang
    Mazieres, Julien
    Vansteenkiste, Johan
    Lena, Herve
    Jaime, Jesus Corral
    Gray, Jhanelle E.
    Powderly, John
    Chouaid, Christos
    Bidoli, Paolo
    Wheatley-Price, Paul
    Park, Keunchil
    Soo, Ross A.
    Huang, Yifan
    Wadsworth, Catherine
    Dennis, Phillip A.
    Rizvi, Naiyer A.
    LANCET ONCOLOGY, 2018, 19 (04): : 521 - 536
  • [47] Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial
    Zhang, Zhiye
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
    Jin, Shui-Ling
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Li, Lu-Hao
    Pan, Jie
    Guo, Wen-Zhi
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
  • [49] Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma
    Di Huang
    Pengfei Cui
    Ziwei Huang
    Zhaozhen Wu
    Haitao Tao
    Sujie Zhang
    Rong Xiang
    Yi Hu
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 881 - 891
  • [50] A single-arm, open phase II clinical trial of anti programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345